The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.
Investigators assessed a 2-part study to investigate the prognostic impact of certain clinical features and genomic markers for rucaparib in treating patients with relapsed high-grade ovarian carcinoma.
The long-term equivalence trial examined the rates of ipsilateral breast tumor recurrence for patients receiving electron intraoperative radiotherapy and whole-breast irradiation at 5-, 10-, and 15-year follow-up times.
E. David Crawford, MD, spoke about the use of transitional disease and other redefined disease states in prostate cancer, while Rana McKay, MD emphasized the need for clinical trials to validate current treatments and practices.
Reducing caloric and nutrient intake for patients who were overweight or obese and undergoing induction for B-cell acute lymphoblastic leukemia was feasible and improved patient response, according to an early-phase trial.
The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.
Research focusing on first-line single-agent carboplatin was terminated due to an independent data monitoring committee’s recommendation after worse survival outcomes were observed in adult patients with ovarian cancer.